136 related articles for article (PubMed ID: 27218683)
21. Carotid Artery Temperature Reduction with Statin Therapy in Patients with Familial Hyperlipidemia Syndromes.
Benetos G; Galanakos S; Koutagiar I; Skoumas I; Oikonomou G; Drakopoulou M; Karmpalioti M; Katsi V; Tsioufis C; Toutouzas K
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768528
[TBL] [Abstract][Full Text] [Related]
22. Treatment Thresholds and ASCVD Risk.
Bittner V
J Am Coll Cardiol; 2021 Oct; 78(15):1508-1510. PubMed ID: 34620407
[No Abstract] [Full Text] [Related]
23. Lipid lowering in patients 75 years and older.
Makhmudova U; Schulze PC; Davis HR; Weingärtner O
World J Cardiol; 2021 Oct; 13(10):526-532. PubMed ID: 34754397
[TBL] [Abstract][Full Text] [Related]
24. A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative change.
Zhang H; Chhibber A; Shaw PM; Mehrotra DV; Shen J
NPJ Genom Med; 2022 Jun; 7(1):33. PubMed ID: 35680959
[TBL] [Abstract][Full Text] [Related]
25. The clinical effect of Xuezhikang combined with ezetimibe in the treatment of coronary heart disease in lipid-lowering treatment and its influence on blood lipid level.
Guo L; Zhao S; Zhao W
Panminerva Med; 2023 Sep; 65(3):426-427. PubMed ID: 34931509
[No Abstract] [Full Text] [Related]
26. All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.
De Caterina R; Salvatore T; Marchioli R
Data Brief; 2016 Jun; 7():1541-50. PubMed ID: 27222850
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
Tsujita K; Yamanaga K; Komura N; Sakamoto K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
Eur J Prev Cardiol; 2016 Sep; 23(14):1524-8. PubMed ID: 27296705
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
[TBL] [Abstract][Full Text] [Related]
29. Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study.
Olotu BS; Shepherd MD; Novak S; Lawson KA; Wilson JP; Richards KM; Rasu RS
Am J Cardiovasc Drugs; 2016 Oct; 16(5):377-90. PubMed ID: 27272032
[TBL] [Abstract][Full Text] [Related]
30. Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk.
Lin I; Sung J; Sanchez RJ; Mallya UG; Friedman M; Panaccio M; Koren A; Neumann P; Menzin J
J Manag Care Spec Pharm; 2016 Jun; 22(6):685-98. PubMed ID: 27231796
[TBL] [Abstract][Full Text] [Related]
31. Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.
Liu CH; Chen TH; Lin MS; Hung MJ; Chung CM; Cherng WJ; Lee TH; Lin YS
J Clin Endocrinol Metab; 2016 Aug; 101(8):2994-3001. PubMed ID: 27270238
[TBL] [Abstract][Full Text] [Related]
32. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
McDonagh M; Peterson K; Holzhammer B; Fazio S
J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792
[TBL] [Abstract][Full Text] [Related]
33. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
Eisen A; Cannon CP; Blazing MA; Bohula EA; Park JG; Murphy SA; White JA; Giugliano RP; Braunwald E;
Eur Heart J; 2016 Dec; 37(48):3576-3584. PubMed ID: 27569841
[TBL] [Abstract][Full Text] [Related]
34. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
[TBL] [Abstract][Full Text] [Related]
35. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
36. Liver fat accumulation is associated with circulating PCSK9.
Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
[TBL] [Abstract][Full Text] [Related]
37. Statin use and the risk of developing diabetes: a network meta-analysis.
Thakker D; Nair S; Pagada A; Jamdade V; Malik A
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1131-1149. PubMed ID: 27277934
[TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
